您要查找的是不是：
- MIXED過(guò)程Mixed procedure
- MIXED-CONTROLMIXED-CONTROL
- mixed congruence method (計算數學(xué))混合同余法
- mixed hyperlipoproteinemia type Ⅰ and Ⅳ高乳糜微粒血癥及前β脂蛋白增高(Ⅰ型和Ⅳ型混合型高脂蛋白血癥, 即Ⅴ型高脂蛋白血癥)
- mixed capillarycavernous hemangioma混合性毛細血管-海綿狀血管瘤
- mixed cellularity type of Hodgkins disease混合型何杰金氏病
- Mixed-HSCT后應用DLI+IL-2,可能是有效提高長(cháng)期生存率的免疫生物治療措施之一。Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently.
- 在理解切換到SQL Server Mixed Mode安全性的安全意義之前,最好保留為默認模式。It's a good idea to leave the default until you understand the security implications of switching to SQL Server Mixed Mode security.
- 經(jīng)過(guò)1~5年觀(guān)察,8例患者M(jìn)ixed-HSCT后應用DLI+IL-2治療的患者長(cháng)期生存率為62.5%。Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%25. There were no GVHD.
- mixed -HSCT :19/ 3 3例 (2 4.2% )復發(fā)死亡 ; 6/ 3 3例 (18.2% )移植相關(guān)死亡 ;mixed-HSCT:8/33(24.2%25) patients died from TRM and 6/33(18.2%25)from relapse;
- 如果您想用另一個(gè)用戶(hù)名密碼對進(jìn)行SQL Server認證,請選擇Mixed Mode并輸入適當的信息。If you want to have a different username password pair for SQL Server Authentication, select Mixed Mode and enter the appropriate information.
- 方法8例急性髓性白血病患者在完全緩解期實(shí)施了Mixed-HSCT,于造血恢復后,給予DLI+IL-2治療2~7次,并隨訪(fǎng)觀(guān)察臨床療效。MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times.
- Mixed過(guò)程提供了豐富的協(xié)方差結構，可以充分利用重復測量資料的信息，又能處理缺失值，是重復測量資料最優(yōu)的統計分析方法。And the MIXED procedure of the SAS System provides a rich selection of covariance structures through the RANDOM and REPEATED statements.
- 本文提出了一種簡(jiǎn)單的可擴展性QoS路由算法Single Mixed Metric based on Link-States,簡(jiǎn)稱(chēng)SMM_LS算法,是改進(jìn)的Dijk-stra算法。This paper proposes a simple scalable QoS routing algorithm-single mixed metric based on link_states, SMM_LS for short, which is a modified Dijkstra algorithm.
- 目的探討急性髓性白血病在經(jīng)過(guò)混合造血干細胞移植(mixed-HSCT)后,應用供體淋巴細胞輸注(DLI)+白介素-2(IL-2)作為后續免疫生物治療措施的意義。Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.
